Cadth 2015 a7 cnesh panel slides htx v3 john
Download as PPTX, PDF0 likes217 views
The document discusses horizon scanning challenges and alternative approaches. It provides an overview of HTX, a Canadian non-profit that supports medtech projects through financing and market access initiatives. HTX could help support CNESH through national registries like RISE (for medtech companies) and REACH (for innovative technologies). The document also reviews international horizon scanning organizations and differences in their priorities, noting the need for horizon scanning to focus more on technologies with real impact and value.
![23 International Scanning Organizations:
Are there complementarities or collaboration potentials?
• EuroScan (20 government-funded members)
• AHRQ
• U.S. Centers for Medicare & Medicaid Services (CMS)
• U.S. Food and Drug Administration (FDA)
• U.S. Center for Disease Control and Prevention (CDC)
• Private organizations: ECRI Institute, Frost and
Sullivan, Hayes, Ingenix, and Thomson Reuters.
EuroScan includes the following:
• Agencia de Evaluación de Tecnologías Sanitarias
(AETS). Instituto de Salud Carlos III, Spain
• Agencia de Evaluación de Tecnologías Sanitarias de
Andalucía, Spain (AETSA)
• Agenzia nationale per i servizi sanitari regionali, Italy
(Age.na.s)
• Australia and New Zealand Horizon Scanning
Network, Australia and New Zealand (ANZHSN,
including Adelaide Health Technology Assessment
[AHTA])
• Basque Office for Health Technology Assessment,
Basque Country (OSTEBA)
• Canadian Agency for Drugs and Technologies in
Health, Canada (CADTH)
EuroScan - continued:
• Committee for Evaluation & Diffusion of Innovative
Technologies, France (CEDIT)
• Council of the Netherlands, The Netherlands (GR)
• Danish Centre for Evaluation and Health Technology
Assessment, Denmark (DACEHTA)
• Division of Medical Technology Policy, Ministry of
Health, Israel (DMTP)
• German Institute for Medical Documentation and
Information, Germany (DIMDI)
• Haute Autorité de Santé, France (HAS)
• Health Information & Quality Authority, Ireland
(HIQA)
• Italian Horizon Scanning Project, Servizio
Farmaceutico Territoriale, Italy (IHSP)
• Ludwig Boltzmann Institute for Health Technology
Assessment, Austria (LBI-HTA)
• Managed Uptake of Medical Methods programme,
Finnish Office for Health Technology Assessment,
Finland (Finohta [MUMM])
• National Horizon Scanning Centre, England (NHSC)
• Norwegian Knowledge Centre for the Health
Services, Norway (NOKC)
• Swedish Council on Technology Assessment in Health
Care, Sweden (SBU)
• Swiss Federal Office of Public Health, Switzerland
(SFOPH)](https://image.slidesharecdn.com/cadth2015a7cneshpanelslideshtxv3john-150413113543-conversion-gate01/85/Cadth-2015-a7-cnesh-panel-slides-htx-v3-john-4-320.jpg)
Cadth 2015 a7 cnesh panel slides htx v3 john
- 1. CNESH Horizon Scanning: Challenges and Alternative Approaches. John Soloninka, PEng MBA President and CEO, HTX jsoloninka@htx.ca
- 2. • Private non-profit corporation. • Leading Canadian supporter of medtech. – Project financing – Support, ecosystem information broker and network. Connectivity. • De-risking technologies and business plans. • Multiple foreign market access initiatives. • $21.4M HTCP fund – 38 financings – $86M total project value • NEW REACH Innovation Procurement Fund 33 Portfolio Companies
- 3. Thoughts… • Quick observations on Horizon Scanning • Value Proposition? • How HTX-led Initiatives might support CNESH –National RISE Medtech Ecosystem Registry –REACH Innovative Technology Registry
- 4. 23 International Scanning Organizations: Are there complementarities or collaboration potentials? • EuroScan (20 government-funded members) • AHRQ • U.S. Centers for Medicare & Medicaid Services (CMS) • U.S. Food and Drug Administration (FDA) • U.S. Center for Disease Control and Prevention (CDC) • Private organizations: ECRI Institute, Frost and Sullivan, Hayes, Ingenix, and Thomson Reuters. EuroScan includes the following: • Agencia de Evaluación de Tecnologías Sanitarias (AETS). Instituto de Salud Carlos III, Spain • Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, Spain (AETSA) • Agenzia nationale per i servizi sanitari regionali, Italy (Age.na.s) • Australia and New Zealand Horizon Scanning Network, Australia and New Zealand (ANZHSN, including Adelaide Health Technology Assessment [AHTA]) • Basque Office for Health Technology Assessment, Basque Country (OSTEBA) • Canadian Agency for Drugs and Technologies in Health, Canada (CADTH) EuroScan - continued: • Committee for Evaluation & Diffusion of Innovative Technologies, France (CEDIT) • Council of the Netherlands, The Netherlands (GR) • Danish Centre for Evaluation and Health Technology Assessment, Denmark (DACEHTA) • Division of Medical Technology Policy, Ministry of Health, Israel (DMTP) • German Institute for Medical Documentation and Information, Germany (DIMDI) • Haute Autorité de Santé, France (HAS) • Health Information & Quality Authority, Ireland (HIQA) • Italian Horizon Scanning Project, Servizio Farmaceutico Territoriale, Italy (IHSP) • Ludwig Boltzmann Institute for Health Technology Assessment, Austria (LBI-HTA) • Managed Uptake of Medical Methods programme, Finnish Office for Health Technology Assessment, Finland (Finohta [MUMM]) • National Horizon Scanning Centre, England (NHSC) • Norwegian Knowledge Centre for the Health Services, Norway (NOKC) • Swedish Council on Technology Assessment in Health Care, Sweden (SBU) • Swiss Federal Office of Public Health, Switzerland (SFOPH)
- 5. Horizon Scanning Examples Show Wide Divergence Health System Priorities and Local Innovation Sector Influences Results All of the lists are unique….no overlap?! Could be due to criteria, health systems, local technologies…
- 6. NHSC Evaluation: Sensitivity, specificity, and predictive values of NHSC’s prediction methods. Estimated wrt expert opinion of the impact 3 to 5 years after prediction. • Sensitivity 71% (95% CI, 0.36–0.92), • Specificity 73% (95% CI, 0.64–0.8), • NPV 98% (95% CI, 0.92–0.99), and • PPV 14% (95% CI, 0.06–0.3). The authors concluded that NHSC methods were .. “reasonably good at identifying lower priority developments, but tended to assign significance to more topics than the experts considered significant in their later practice.”
- 7. Challenges… • Increasing relevance? • Getting more nominations? • HTX-led Initiatives might support CNESH –National RISE Medtech Ecosystem Registry –REACH Innovative Technology Registry
- 8. Possible Directions… • For Regulators – Focus on new science discoveries and capabilities introducing new risks or requiring new reg. science. • Eg. BYOD mobile diagnostics; radical material properties; new imaging modalities; implantable sensors; closed loop artificial organs; self appendectomy iPhone apps. – Focus less on cool devices that are not new from a regulatory science or clinical trial perspective. • For HTA bodies – Focus on “cross silo” or “lean” technologies that show dramatic potentially to increase quality at reduced cost. – Focus on technologies that could fundamentally alter existing treatment pathways for dramatic effect. • For Procurement and Providers – Focus on technologies showing realized value, not potential. – Focus on 10x, 5x, 2x benefits actually achieved! – Allow industry to self report…based on demonstrated evidence.
- 9. RISE – Medtech Ecosystem Database Registry of Innovators, Suppliers and Exporters Vancouver Toronto Montreal Alberta 6% British Columbia 11% Manitoba 4% New Brunswick 1% Newfoundland 0% Nova Scotia 2% Nunavut 0% Ontario 56% PEI 0% Quebec 19% Saskatchewan 1% Yukon 0% Total Provincial Aggregate
- 10. Registry of Canadian Medtech Innovators, Suppliers and Exporters WHAT IS RISE? A SUSTAINABLE ONLINE REGISTRY OF MEDTECH ENTITIES 2,700+ MEDTECH RISE PLAYERS MANUFACTURERS GOVERNMENT ORGANIZATIONS/NPO DISTRIBUTORS INVESTORS SERVICE PROVIDERS/CONSULTANTS MEDIA R&D SERVICES 208 63 929 594 382 545 16 BENEFITS TO REGISTERING? Improves LOCAL & INTERNATIONAL VISIBLITY for your COMPANY IDENTIFIES competition and relevant players in Medtech space enables opportunities ADVANTAGEOUS partnership COST-FREE & EASY REGISTRATION! ~3,000
- 12. REACH: A New Innovation Procurement Program. (Highlighted in the “Evidence is Not Enough” Panel) Technology/Product Development/ Validation Maturing/ Evidence Generation Scale: Diffusion/ Export - Local, Global Intake (Pipeline) Ontario Sales $ MNEs SMEs Academic Spinoffs US EU ROC China Ont US EU Rest of Canada China Ontario HTX REACH Traditional Innovation Support Pre-Market Development Post-Market Evaluation and Adoption Foreign Market Access
- 13. REACH Planned Registries • Innovative Technology Registry – To support procurement and providers – “What innovative technologies are out there?” – ‘What has worked well?” – Pre/Post market technologies – so less speculative – Can be linked to the Problem Registry below. • Health System Problem Registry – To inform innovators of H/S Needs & Priorities – Three possible classes • Generic (e.g. Deskilling, setting of care change, lean etc.) • Reform driven e.g. (5% focus, QBPs, etc.) • Clinical Priorities (eg. Re-admits on CHF, Dx Apnea, ALCs, etc.)
Editor's Notes
- #10: Canada has three major life science clusters: Vancouver, Toronto and Montreal. In addition, we have concentrations of life science commercialization surrounding a large number of our world-class university teaching hospitals in other centres. Given my short time today, let me focus on the largest cluster, Southern Ontario. Where Montreal, Vancouver and Ontario all place emphasis on drugs, biologics and diagnostics, our Southern Ontario cluster has a definite focus on medtech.